Stock Rating Runner: Xtant Medical (XTNT) Is A Stock Aegis Capital Is Interested In

November 30, 2016 - By olga

Stock Rating Runner: Xtant Medical (XTNT) Is A Stock Aegis Capital Is Interested In

Why Aegis Capital Gives Xtant Medical (XTNT) $3.5 Price Target

Aegis Capital issued a Buy rating on Xtant Medical (XTNT). The firm has started coverage on shares of XTNT in a a research note shared with investors on Wednesday, 30 November. Aegis Capital’s target price per share would suggest upside of 608.50% from the company’s last stock price.

About 557,474 shares traded hands or 268.89% up from the average. Xtant Medical Holdings Inc (XTNT) has declined 79.41% since April 27, 2016 and is downtrending. It has underperformed by 84.64% the S&P500.

Analysts await Xtant Medical Holdings Inc (NYSEMKT:XTNT) to report earnings on March, 21. They expect $-0.20 EPS, up 51.22% or $0.21 from last year’s $-0.41 per share. After $-0.40 actual EPS reported by Xtant Medical Holdings Inc for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, makes and markets regenerative medicine products and medical devices for domestic and international markets. The company has a market cap of $6.79 million. The Firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. It currently has negative earnings. The Company’s biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts.

According to Zacks Investment Research, “Xtant Medical Holdings, Inc. develops, manufactures and markets biologics products. The Company’s product used in an applications which includes enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., is based in Belgrade, United States.”

XTNT Company Profile

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., incorporated on August 8, 2006, develops, makes and markets regenerative medicine products and medical devices for domestic and international markets. The Firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. The Company’s biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and a range of 3Demin products, as well as other allografts. The Company’s products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries.

More news for Xtant Medical Holdings Inc (NYSEMKT:XTNT) were recently published by: Streetinsider.com, which released: “Xtant Medical Holdings (XTNT) Granted FDA Clearance for the Xsert Lumbar …” on November 23, 2016. Globenewswire.com‘s article titled: “Xtant Medical Announces FDA Approval of OsteoSelect(R) PLUS” and published on August 25, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>